Skip to Content
Merck
CN

H-922

α-Hydroxymidazolam solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C18H13ClFN3O
CAS Number:
59468-90-5
Molecular Weight:
341.77
NACRES:
NA.24
UNSPSC Code:
41116107

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

α-Hydroxymidazolam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

concentration

1.0 mg/mL in methanol

technique(s)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

InChI

1S/C18H13ClFN3O/c19-11-5-6-16-14(7-11)18(13-3-1-2-4-15(13)20)22-9-12-8-21-17(10-24)23(12)16/h1-8,24H,9-10H2

InChI key

QHSMEGADRFZVNE-UHFFFAOYSA-N

SMILES string

OCc1ncc2CN=C(c3ccccc3F)c4cc(Cl)ccc4-n12

grade

certified reference material

form

liquid

feature

Snap-N-Spike®/Snap-N-Shoot®

packaging

ampule of 1 mL

manufacturer/tradename

Cerilliant®

application(s)

clinical testing

format

single component solution

storage temp.

2-8°C

Quality Level

300

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

α-Hydroxymidazolam is an active, major metabolite in urine and blood of the benzodiazepine midazolam. Midazolam is sold as Dormicum, Hypnovel®, and Versed as a sedative and treatment for insomnia and seizures. This Certified Spiking Solution® is suitable as starting material for use in calibrators or controls for a variety of LC/MS or GC/MS applications from forensic analysis and clinical toxicology to urine drug testing.

Legal Information

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Hypnovel is a registered trademark of Hoffman-LaRoche & Co. AG
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

target_organs

Eyes

Storage Class

3 - Flammable liquids

wgk

WGK 2

flash_point_f

49.5 °F - closed cup

flash_point_c

9.7 °C - closed cup

Regulatory Information

危险化学品
This item has

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Camilla Svanström et al.
Journal of pharmaceutical and biomedical analysis, 58, 71-77 (2011-10-14)
The metabolic conversion of midazolam (MDZ) to its main metabolite 1'-hydroxy-midazolam (1-OH-MDZ) can be used as a probe drug for cytochrome P450 3A (CYP3A) activity. A sensitive method for the simultaneous determination of MDZ and its metabolite 1-OH-MDZ in human
Xinping Xue et al.
Journal of pharmaceutical and biomedical analysis, 55(1), 187-193 (2011-02-15)
In order to simultaneously determine in vivo P-glycoprotein (P-gp) and Cytochrome P450 3A (CYP3A) activity, a new, rapid and sensitive liquid chromatography/tandem mass spectrometry (LC-MS/MS) method has been developed and fully validated to simultaneously determine midazolam (MDZ, as CYP3A substrate)
David Hostler et al.
Drug metabolism and disposition: the biological fate of chemicals, 38(5), 781-788 (2010-02-19)
The clinical use of therapeutic hypothermia has been rapidly expanding due to evidence of neuroprotection. However, the effect of hypothermia on specific pathways of drug elimination in humans is relatively unknown. To gain insight into the potential effects of hypothermia
Kristin Samuelsson et al.
Xenobiotica; the fate of foreign compounds in biological systems, 42(11), 1128-1137 (2012-05-31)
The pharmacokinetics and biotransformation of midazolam were investigated following single oral doses of 0.1, 1 and 10 mg/kg to chimeric mice with humanised livers (PXB mice) and to severe combined immunodeficient (SCID) mice used as controls. Pharmacokinetic analysis, on whole
Stephanie Katzenmaier et al.
European journal of clinical pharmacology, 66(11), 1137-1141 (2010-08-04)
Midazolam metabolic clearance to 1'-hydroxymidazolam is an accurate measure of CYP3A activity which requires extensive plasma and urine sampling. The objective of this study was to find a new limited sampling strategy (LSS) to predict midazolam metabolic clearance to 1'-hydroxymidazolam
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service